Pharmaceutical M&A: Private Equity’s Return in 2025

Blackstone Inc. Is leading a $1.3 billion financing package to support the merger of Paratek Pharmaceuticals Inc. And Radius Health Inc., signaling a renewed appetite for private equity investment in the pharmaceutical sector. The deal, arranged by Blackstone Credit & Insurance, includes over $400 million from Sixth Street Partners, with additional contributions from Oaktree Capital Management and Silver Point Capital, according to individuals familiar with the transaction.

The financing comes as the pharmaceutical mergers and acquisitions landscape shows signs of recovery after a period of relative dormancy. According to industry observers, rising healthcare consumerization, self-care trends, and cost-containment measures are creating new opportunities for private equity firms to invest in the space. Large pharmaceutical companies are also increasingly turning to outsourcing, further fueling M&A activity.

The deal reflects Blackstone’s capacity to “provide large-scale capital solutions to life sciences companies,” as stated by a representative with knowledge of the transaction. The specifics of the merger between Paratek and Radius Health, including the terms and anticipated synergies, remain undisclosed. However, the substantial financial backing suggests a significant strategic realignment within the pharmaceutical industry.

Several private equity firms are actively seeking deals in the pharmaceutical sector. Baymark Partners, for example, has closed six deals via Axial, an M&A platform, since June 2023, focusing on middle-market companies in IT, healthcare, and related services. Axial currently lists 165 pharmaceutical private equity funds actively sourcing deals, indicating a competitive environment for potential acquisitions.

PwC’s 2026 outlook for US pharmaceutical and life sciences M&A highlights the increasing importance of precision-led biopharma deals, pressures related to loss of exclusivity for existing drugs, and the growing trend of cross-border licensing agreements. Alternative capital structures are also gaining traction as companies seek innovative financing solutions.